Thymosin Alpha-1 Compounding Legal Status: FDA Rules, 503A/503B Access, and What Patients Need to Know

HealthRX.com

Not FDA-approved, and no clear US compounding path

Print or save as PDF

Key numbers

  • 17 noAdvisory committee votes against adding thymosin alpha-1 to the pharmacy bulks list (4 yes, 17 no)Source: fda.gov, as cited Nov 7, 2026
  • 1.6 mgStrength of the Zadaxin injection sold outside the US, which is not interchangeable with bulk powderSource: fda.gov, as cited Nov 7, 2026
  • 4 weeksCourse length in the Italian Zadaxin label, starting at the first vaccinationSource: fda.gov, as cited Nov 7, 2026
  • FDA approval status / Not approved; four US orphan drug designations only [1]
  • State-licensed pharmacy list, updated May 14, 2026 / In none of the three categories [2]
  • Outsourcing facility list, updated March 21, 2025 / Category 3, nominated without adequate support [3]
  • Advisory committee vote, December 4, 2024 / 4 yes, 17 no, no abstentions [4]
  • FDA safety concerns still posted / Immunogenicity for certain routes; peptide impurities and characterization problems [5]
  • HHS October 2026 peptide policy / Not among the six named peptides [6]
  • Approvals outside the US, per FDA / Italy, India, Hong Kong; brand Zadaxin [1]
  • WADA Prohibited List / Not named on the 2026 list; thymosin-beta-4 and TB-500 are [7]

Is thymosin alpha-1 FDA-approved in the US?

No. A search of Drugs@FDA returns no US application for thymosin alpha-1 (thymalfasin) [1]. It does hold four US orphan drug designations, but orphan designation is a separate process from approval or licensing, and a designation on its own does not authorize marketing [1][8].

Zadaxin is the finished 1.6 mg injection sold outside the US; it is not interchangeable with bulk thymosin alpha-1 powder [1].

Where it sits on FDA's compounding lists

FDA keeps separate lists for the two compounding pathways.

For state-licensed pharmacies and physicians, FDA's list updated May 14, 2026 places thymosin alpha-1 in none of its three categories [2].

For outsourcing facilities, FDA's list updated March 21, 2025 puts it in category 3, 'nominated without adequate support' [3]. FDA describes category 3 as substances nominated with insufficient supporting information for the agency to evaluate; they are outside the category 1 policy under which FDA says it generally does not intend to act against compounders, and FDA says it would consider action under its general enforcement policies [9]. A category 3 substance can be re-nominated with better supporting information [9].

No FDA or HHS action allowing compounding of thymosin alpha-1 is known [6].

What people on Reddit report

Reddit comments from a tirzepatide compounding thread about state-board and federally registered pharmacy rules. These are not thymosin alpha-1 accounts. They show how the same bulk-list process is playing out for another drug.

Junior_Commission588 · tirzepatidecompound

The 503as don't have the same set of inspection/rules. No one truly knows what will end up happening with them.

Commenter says state-board pharmacies are not held to the same inspection rules as federally registered sites, and the outcome for them is unclear. Drug discussed: tirzepatide.

Read the source discussion

IFeartheWiggles · tirzepatidecompound

If compounding takes a hit it's more likely to start with 503A's.

Commenter thinks federally registered sites face more legal pressure from the manufacturer, but expects any limit on compounding to start with state-board pharmacies. Drug discussed: tirzepatide.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

FDA's safety concerns are still on the record

FDA's page on bulk substances that may present significant safety risks, with content dated April 22, 2026, lists thymosin alpha-1 in the table of substances that were 'nominated but withdrawn': it had been in category 2 and came off that list after the nominators withdrew [5]. The concerns FDA stated are still published on that page: a 'significant risk for immunogenicity for certain routes of administration', peptide-impurity and characterization problems, and safety information FDA called 'inadequate for the agency to sufficiently understand the extent of any safety issues' [5].

The December 2024 advisory committee vote

FDA proposed that thymosin alpha-1 not be added to the pharmacy bulks list. On December 4, 2024, the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate [4]. Members who voted no cited no compelling evidence of clinical effectiveness and safety; some who voted yes said patients should have access [4].

Is it covered by the October 2026 HHS peptide policy?

No. HHS's October 2026 draft enforcement-discretion policy names six peptides (BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500), and thymosin alpha-1 is not among them [6]. Thymosin beta-4 and its derivative TB-500 are different peptides from thymosin alpha-1 [7].

Where it is approved, and for what

FDA's December 2024 review lists three national authorizations: Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 and older with compensated liver disease and virus replication; and Hong Kong [1]. A SciClone 2014 annual report describes approvals in parts of Asia-Pacific, Latin America, Eastern Europe and the Middle East, mostly for hepatitis B and as a vaccine adjuvant, and FDA said it could not independently verify those broader claims [1].

In Europe, the EMA has granted only an orphan designation, for hepatocellular carcinoma, which is not a marketing approval [1].

Two older reviews, both by authors tied to the Zadaxin developer, state approval in 'over 35 countries' in 2009 and 'more than 30 countries' in 2007 [10][11]. Those figures come from those two reviews, not from a current regulatory database.

Dose and label cautions

There is no US-approved dose [1]. The Italian label for Zadaxin 1.6 mg powder gives it subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination [1]. The same label says not for children, contraindicated in pregnancy and breastfeeding, use caution in people with allergies or autoimmune disease, and caution with other immune-modulating drugs [1].

What the hepatitis B trials show

The 2026 Cochrane review pooled 10 randomized trials with 1,349 adults, published 1991 to 2018 in Bangladesh, China, Italy, Korea, Singapore and Taiwan [12]. It found possible lower all-cause mortality with thymosin alpha-1 (risk ratio 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people) at very low certainty, little to no effect on quality of life or on liver histology, and a very uncertain effect on hepatitis B-related illness; the reviewers said they are 'not sure' it helps [12].

Smaller trials point in mixed directions. In a double-blind trial of 98 adults, adding thymosin alpha-1 to lymphoblastoid interferon produced HBeAg loss at 72 weeks of 45.8% versus 28.0% (difference 17.8%, 95% CI -1.2 to 35.3, P=0.067), which was not statistically significant [13]. A very small 1991 pilot of 12 people, seven of whom received thymosin fraction 5 or thymosin alpha-1, reported HBV DNA clearance in 6 of 7 versus 1 of 5 on placebo (P<0.04) [14].

What is known about adverse effects

FDA searched its adverse-event database on April 22, 2024 and found zero reports for thymosin alpha-1 [1]. Authors tied to the manufacturer report more than 4,400 people enrolled in trials and more than 17 million doses of Zadaxin given after marketing, with adverse experiences described as 'infrequent and mild'; treat that as company-linked data [1].

The Cochrane review found that thymosin alpha-1 may have caused fewer serious adverse events than comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) and fewer non-serious events (risk ratio 0.47, 95% CI 0.27 to 0.83; very low-certainty evidence) [12].

Is it banned in sport?

Thymosin alpha-1 is not named on WADA's 2026 Prohibited List [7]. WADA does name thymosin-beta-4 and derivatives such as TB-500 in the growth-factor section S2.3, which is a different peptide [7]. WADA's S0 category covers substances with no approval from any governmental health authority, and thymosin alpha-1 is approved in some countries [7][1].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. According to the article, what does a search of Drugs@FDA show for thymosin alpha-1?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Is thymosin alpha-1 FDA-approved?
No. Drugs@FDA lists no US application for it, and its four US orphan drug designations are not approvals [1][8].
Can a state-licensed pharmacy compound thymosin alpha-1?
On FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, the peptide appears in none of the three categories, and FDA's advisory committee voted 17 no to 4 yes against adding it to the pharmacy bulks list [2][4].
What about outsourcing facilities?
On FDA's list for outsourcing facilities, updated March 21, 2025, it is category 3, nominated without adequate support, which is outside the category 1 policy [3][9].
Where is thymosin alpha-1 approved?
FDA lists Italy, where Zadaxin is an adjuvant to influenza vaccination in immunocompromised people, India for chronic hepatitis B in adults with compensated liver disease, and Hong Kong; the EMA has only an orphan designation for liver cancer [1].
Is thymosin alpha-1 on the WADA Prohibited List?
It is not named on WADA's 2026 Prohibited List. WADA names thymosin-beta-4 and TB-500 in section S2.3, which are different peptides [7].
What side effects are reported with thymosin alpha-1?
FDA's search of its adverse-event database in April 2024 returned zero reports [1]. In a 2026 Cochrane review it may have caused fewer serious adverse events than comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1056 people; low-certainty evidence) [12].
Show all 15 referencesHide references
  1. U.S. Food and Drug Administration.
  2. U.S. Food and Drug Administration.
  3. U.S. Food and Drug Administration.
  4. U.S. Food and Drug Administration.
  5. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  6. Official web page.
  7. World Anti-Doping Agency.
  8. Designating an Orphan Product: Drugs and Biological Products | FDA.
  9. Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
  10. Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608.
  11. Tuthill C. Issues in pharmaceutical development of thymosin alpha1 from preclinical studies through marketing. Ann N Y Acad Sci. 2007;1112:351-6.
  12. Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026;9(9):CD014610.
  13. Lim SG, Wai CT, Lee YM, Dan YY, Sutedja DS, Wee A, et al. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther. 2006;11(2):245-53.
  14. Mutchnick MG, Appelman HD, Chung HT, Aragona E, Gupta TP, Cummings GD, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology. 1991;14(3):409-15.
  15. Reddit participants. Opinions on 503a vs. 503b pharmacies (r/tirzepatidecompound). Accessed 2026-11-11.
Evidence overview for Thymosin Alpha-1 Compounding Legal Status: FDA Rules, 503A/503B Access, and What Patients Need to Know